HomeCommentary

Commentary

Taltz Issue Exposes Forex-Sensitive Nature of Drug Pricing System
(Nov.15.2016)

With bumps and detours and much industry attention, Eli Lilly’s psoriasis drug Taltz (ixekizumab) is finally set to join the NHI reimbursement price list later this week. It was priced once in August, followed by Lilly’s withdrawal of its listing request, and then priced again this month - at a much lower price. The cause of the price gap: currency fluctuations. The issue has laid bare the susceptibility of our drug pricing system to foreign exchange moves ...

(LOG IN FOR FULL STORY)

News Calendar